Niralin Shah News Today

Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy.

The FDA approval of the first CAR T-cell therapy for children and young adults with B-cell ALL changed the treatment paradigm for this disease.

Blogs | | Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among patients with relapsed or refractory B-cell acute lymphoblastic leukemia.Despite that, 50% of patients relapse after CAR-T therapy, and curative options for patients who relapse after CD19 CAR-T are limited, with no standard approach to cure.

The FDA approval of the first CAR T-cell therapy for children and young adults with B-cell ALL changed the treatment paradigm for this disease.

New ways to use CAR T-cell therapy and treatment de-intensification strategies

Analysis shows safety and outcomes equivalent to those reported in older children

Stem cell transplants offer long-term benefits for pediatric cancer patients receiving immunotherapy Apr 1 2021 Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds. Daniel "Trey" Lee is conducting pioneering clinical research in the battle against childhood cancer. Ima...